atezolizumab,bevacizumab
roche
['atezo', 'hcc', ' bev ', 'bcsm', 'imbrave050']
the #oncoalerttoptweet day1 of #asco23 tweet by our oncoalert faculty imbrave050 adjuvant atezo bev for hepatocellular cancer (hcc) #hpbcsm.
78% 65% 12 month rfs rate. best 
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨